Watchlist Price Alert

Syndax Pharmaceuticals In... (SNDX)

NASDAQ: SNDX · Real-Time Price · USD

9.27

-0.92 (-9.03%)

At close: May 14, 2025, 3:59 PM

9.31

0.43%

After-hours: May 14, 2025, 07:51 PM EDT

-9.03% (1D)

Bid	9
Market Cap	797.66M
Revenue (ttm)	43.72M
Net Income (ttm)	-331.2M
EPS (ttm)	-3.85
PE Ratio (ttm)	-2.41
Forward PE	-3.91
Analyst	Buy

Ask	11.3
Volume	2,363,094
Avg. Volume (20D)	2,170,365
Open	10.18
Previous Close	10.19
Day's Range	9.26 - 10.45
52-Week Range	9.26 - 25.07
Beta	0.82

About SNDX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SNDX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SNDX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Syndax Pharmaceuticals has released their quartely earnings on May 5, 2025:

Revenue of $20.04M exceeds estimates by $3.86M, with Infinity% YoY growth.

EPS of -0.98 exceeds estimates by 0.29, with -15.29% YoY decline.

Why Price Moved

1 month ago

+7.47%

Syndax Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription

2 months ago

-1.02%

Syndax Pharmaceuticals shares are trading lower after the company reported Q4 financial results and missed its EPS and sales estimate.

News

6 days ago · zacks.com

Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High?

The consensus price target hints at a 220% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate re...

1 week ago · seekingalpha.com

Syndax Pharmaceuticals, Inc. (SNDX) Q1 2025 Earnings Call Transcript

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Sharon Klahre - Head of IR Michael Metzger - Chief Executive Officer and Direct...

1 week ago · zacks.com

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $0.85 per share a year ago.

2 months ago · seekingalpha.com

Syndax Pharmaceuticals, Inc. (SNDX) Q4 2024 Earnings Call Transcript

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q4 2024 Earnings Conference Call March 3, 2025 8:00 AM ET Company Participants Sharon Klahre - Head of IR Michael Metzger - CEO Steve Closter - CCO Neil Gal...

2 months ago · zacks.com

Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.08. This compares to loss of $1 per share a year ago.